Davita Inc.
—- Market cap
- $11.57B
- Debt
- —
- Cash
- −$676.44M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $11.57B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: DVA stock price vs HUM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Implied fair value · at DVA's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DAVITA INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QUEST DIAGNOSTICS INC
DVA vs DGX
WEST PHARMACEUTICAL SERVICES INC
DVA vs WST
BAXTER INTERNATIONAL INC
DVA vs BAX
MCKESSON CORP
DVA vs MCK
Cigna Group
DVA vs CI
LABCORP HOLDINGS INC.
DVA vs LH
UNITEDHEALTH GROUP INC
DVA vs UNH
Elevance Health, Inc.
DVA vs ELV
CVS HEALTH Corp
DVA vs CVS
CENTENE CORP
DVA vs CNC
Oscar Health, Inc.
DVA vs OSCR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DVA can sustain its 15.0% operating margin while managing its 6.0x net debt/EBITDA, then the stock looks attractive to own because it trades below HUM-implied P/E value and inside its historical range.
On a P/E basis, DVA’s current price of $240.09 is well below the implied price of $363.86, suggesting roughly 51.6% upside versus HUM-based valuation. The gap is partly explained by DVA trading at a much lower P/E than HUM, while still showing a stronger operating profile than HUM on margin metrics.
Supporting Metrics